LakeShore Biopharma Amends Go-Private Deal, Cuts Shareholder Payout by 92%

summarizeSummary

LakeShore Biopharma has amended its going-private merger agreement, reducing the per-share consideration from US$0.90 to US$0.066, a 92% cut from the original offer, though still a premium to current trading levels.

check_boxKey Events

• Merger Agreement Amended

  LakeShore Biopharma entered into Amendment No. 1 to its Agreement and Plan of Merger, originally dated November 4, 2025, with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc.

• Per Share Consideration Drastically Reduced

  The cash consideration per ordinary share for the going-private transaction has been reduced from US$0.90 to US$0.066. This new price represents a premium of approximately 46.7% to the closing price on March 24, 2026, and a 137% premium to the current stock price of US$0.0278.

• Termination Fees Lowered

  The Company Termination Fee has been reduced from US$550,000 to US$50,000, and the Parent Termination Fee from US$1,100,000 to US$100,000.

• Company to Go Private

  Upon completion of the merger, expected in Q3 2026, LakeShore Biopharma will become a wholly-owned subsidiary of Oceanpine Skyline Inc., and its shares will no longer be quoted on the OTC Pink Open Market.

auto_awesomeAnalysis

LakeShore Biopharma has finalized an amendment to its going-private merger agreement, drastically reducing the per-share consideration from the original US$0.90 to US$0.066. This represents a significant haircut for shareholders who were expecting the initial offer. While the new offer of US$0.066 is a substantial premium to the current trading price of US$0.0278, it reflects a weakened negotiating position for the company. The transaction, implying an equity value of approximately US$2.7 million, will result in the company becoming a privately held subsidiary and its shares delisting from the OTC Pink Open Market. Additionally, termination fees for both the company and the parent have been significantly reduced, and the agreement includes a carve-out for specific arbitral awards, indicating potential liabilities that the buyer will not consider a Material Adverse Effect.